Abstract:Natural killer (NK) cells have played a critical-if largely unrecognized or ignored-role in the treatment of B cell non-Hodgkin lymphoma (NHL) since the introduction of CD20-directed immunotherapy with rituximab as a cornerstone of therapy over 25 years ago. Engagement with NK cells leading to lysis of NHL targets through antibody-dependent cellular cytotoxicity (ADCC) is a critical component of rituximab's mechanism of action. Despite this important role, the only aspect of B cell NHL therapy that has been adopted as standard therapy that even indirectly augments or restores NK cell function is the introduction of obinutuzumab, a CD20 antibody with enhanced ability to engage with NK cells. However, over the last 5 years, adoptive immunotherapy with effector lymphocytes of B cell NHL has experienced tremendous growth, with five different CAR T cell products now licensed by the FDA, four of which target CD19 and have approved indications for some subtype of B cell NHL-axicabtagene ciloleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, and tisagenlecleucel. These T cell-based immunotherapies essentially mimic the recognition, activation pathway, and cytotoxic machinery of a CD19 antibody engaging NK cells and lymphoma targets. Despite their efficacy, these T cell-based immunotherapies have been difficult to implement because they require 4-6 weeks of manufacture, are costly, and have significant toxicities. This renewed interest in the potential of cellular immunity-and the manufacturing, supply chain, and administration logistics that have been addressed with these new agents-have ignited a new wave of enthusiasm for NK cell-directed therapies in NHL. With high safety profiles and proven anti-lymphoma efficacy, one or more new NK cell-directed modalities are certain to be introduced into the standard toolbox of NHL therapy within the next few years, be it function-enhancing cytokine muteins, multi-domain NK cell engagers, or adoptive therapy with expanded or genetically modified NK cells.

Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma

Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma

The evolving role of targeted drugs in the treatment of Hodgkin lymphoma

Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas

ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma

Taking a BiTE out of Lymphoma: Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma

New targeted therapies for malignant lymphoma based on molecular heterogeneity

Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns and opportunities

Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review

Targeting indolent non-Hodgkin lymphoma

The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL)

Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia

Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy

Could protein kinase inhibitors become a next generation pharmacotherapy for non-Hodgkin's lymphoma?

Novel treatment for mantle cell lymphoma – impact of BTK inhibitors and beyond

CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas

Updating targets for natural killer/T-cell lymphoma immunotherapy

Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas

Advances in the treatment of mantle cell lymphoma with BTK inhibitors

T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions

Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives